Medexus Pharmaceuticals Inc has seen a slight decline in its stock this week, with no major news impacting its performance.
Medexus Pharmaceuticals Inc (MDP.TO) has experienced a modest downturn of 3.44% over the past week, closing at C$5.06. Despite this drop, the stock has performed well year-to-date, showing a notable increase of 63.75%. This week, there have been no significant announcements that could have influenced investor sentiment.
Investor takeaway: Investors should note the recent price movements of Medexus Pharmaceuticals, especially in the context of its recent financial results and market performance. With a solid year-to-date increase, the company continues to show potential, but recent declines warrant a closer look.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.02M
52W high
$5.50
52W low
$2.51
1W change
-3.44%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 43.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+43.3% Upside
Current Price
C$5.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
32.7%
Annualized
90-Day Vol
40.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.37 | C$4.80 โ C$6.01 |
| 60 trading days | C$5.70 | C$4.86 โ C$6.68 |
| 90 trading days | C$6.05 | C$4.98 โ C$7.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
MDP.TO has a market cap of C$159 million and has traded within a 52-week range of C$2.51 to C$5.50.
The stock's beta of 1.83 indicates higher volatility compared to the market, which may lead to larger price swings and increased risk for investors.
Bull case
The bullish outlook is supported by strong product-level performance, particularly of GRAFAPEX (treosulfan), as reported in the fiscal Q1 2027 results. Analysts are optimistic, with an average target of C$7.25, suggesting significant upside potential.
Bear case
On the other hand, the company currently has a negative profit margin and return on equity, raising concerns about its profitability and operational efficiency. The recent decline in stock price may reflect investor caution amid these financial metrics.
Recent Price Action
Advertisement
This week, Medexus Pharmaceuticals Inc (MDP.TO) closed at C$5.06, marking a 3.44% decline over the past week. The stock has shown a year-to-date increase of 63.75%, indicating strong performance despite recent fluctuations.
Company News and Headlines
While there were no major announcements this week, Medexus Pharmaceuticals had previously reported strong performance of GRAFAPEX (treosulfan) in its fiscal Q1 2027 results on August 10, 2026. This has been a key product for the company, contributing to its positive outlook. Additionally, the company scheduled a conference call to discuss these results on July 30, 2026, but no new updates have emerged since then.
Technical Picture
Medexus Pharmaceuticals currently trades above its 50-day moving average of C$5.03, showing a slight increase of 0.6% compared to the current price. The 200-day moving average stands at C$3.72, indicating a significant 35.9% increase from the current price. The stock is trading within 85% of its 52-week range of C$2.51 to C$5.50. With a beta of 1.83, the stock exhibits higher volatility, suggesting that investors should be prepared for potential price swings.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
